-
1
-
-
0029811462
-
Pain caused by bone metastasis in endocrine-therapy-refractory prostate cancer
-
K. Akakura S. Akimoto J. Shimazaki Pain caused by bone metastasis in endocrine-therapy-refractory prostate cancer J Cancer Res Clin Oncol 122 1996 633 637
-
(1996)
J Cancer Res Clin Oncol
, vol.122
, pp. 633-637
-
-
Akakura, K.1
Akimoto, S.2
Shimazaki, J.3
-
2
-
-
0028943667
-
Tumor doubling time in patients with prostate cancer: Determination of prostate-specific antigen and prostatic acid phosphatase doubling time
-
S. Akimoto M. Masai K. Akakura Tumor doubling time in patients with prostate cancer: Determination of prostate-specific antigen and prostatic acid phosphatase doubling time Eur Urol 27 1995 207 212
-
(1995)
Eur Urol
, vol.27
, pp. 207-212
-
-
Akimoto, S.1
Masai, M.2
Akakura, K.3
-
3
-
-
0029991439
-
Phase II study of weekly intravenous recombinant humanized anti-p185 HER2/neu monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
-
J. Baselga D. Tripathy J. Mendelsohn Phase II study of weekly intravenous recombinant humanized anti-p185 HER2/neu monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer J Clin Oncol 14 1996 737 744
-
(1996)
J Clin Oncol
, vol.14
, pp. 737-744
-
-
Baselga, J.1
Tripathy, D.2
Mendelsohn, J.3
-
4
-
-
0016345864
-
Comparison of treatments for prostatic cancer using an exponential-type life model relating survival to concomitant information
-
S. Bayard R. Greenberg D. Showalter Comparison of treatments for prostatic cancer using an exponential-type life model relating survival to concomitant information Cancer Chemother Rep 58 1974 845 859
-
(1974)
Cancer Chemother Rep
, vol.58
, pp. 845-859
-
-
Bayard, S.1
Greenberg, R.2
Showalter, D.3
-
5
-
-
0018663568
-
Prognostic factors in metastatic and hormonally unresponsive carcinoma of the prostate
-
W.R. Berry J. Laszlo E. Cox Prognostic factors in metastatic and hormonally unresponsive carcinoma of the prostate Cancer 44 1979 763 775
-
(1979)
Cancer
, vol.44
, pp. 763-775
-
-
Berry, W.R.1
Laszlo, J.2
Cox, E.3
-
6
-
-
0015973060
-
An exponential model relating censored survival data and concomitant information for prostatic cancer patients
-
D.P. Byar R. Huse J.C. Bailar An exponential model relating censored survival data and concomitant information for prostatic cancer patients J Natl Cancer Inst 52 1974 321 326
-
(1974)
J Natl Cancer Inst
, vol.52
, pp. 321-326
-
-
Byar, D.P.1
Huse, R.2
Bailar, J.C.3
-
7
-
-
0015375422
-
Carcinoma of the prostate: Prognostic evaluation of certain pathologic features in 208 radical prostatectomies
-
D.P. Byar F.K. Mostofi VACURG Carcinoma of the prostate: Prognostic evaluation of certain pathologic features in 208 radical prostatectomies Cancer 30 1972 5 13
-
(1972)
Cancer
, vol.30
, pp. 5-13
-
-
Byar, D.P.1
Mostofi, F.K.2
VACURG3
-
8
-
-
0026021087
-
Independent prognostic factors in patients with metastatic (stage D2) prostate cancer
-
G.W. Chodak N.J. Vogelzang R.I. Caplan Independent prognostic factors in patients with metastatic (stage D2) prostate cancer JAMA 265 1991 618 621
-
(1991)
JAMA
, vol.265
, pp. 618-621
-
-
Chodak, G.W.1
Vogelzang, N.J.2
Caplan, R.I.3
-
9
-
-
0019485158
-
Systemic treatment of advanced prostatic cancer: Development of a new system for defining response
-
D.L. Citrin A.I. Cohen J. Harberg Systemic treatment of advanced prostatic cancer: Development of a new system for defining response J Urol 125 1981 224 227
-
(1981)
J Urol
, vol.125
, pp. 224-227
-
-
Citrin, D.L.1
Cohen, A.I.2
Harberg, J.3
-
10
-
-
0029993112
-
Critical analysis of the ability of the endorectal coil magnetic resonance imaging scan to predict pathologic stage, margin status, and postoperative prostate-specific antigen failure in patients with clinically organ-confined prostate cancer
-
A.V. D'Amico R. Whittington S.B. Malkowicz Critical analysis of the ability of the endorectal coil magnetic resonance imaging scan to predict pathologic stage, margin status, and postoperative prostate-specific antigen failure in patients with clinically organ-confined prostate cancer J Clin Oncol 14 1996 1770 1777
-
(1996)
J Clin Oncol
, vol.14
, pp. 1770-1777
-
-
D'Amico, A.V.1
Whittington, R.2
Malkowicz, S.B.3
-
11
-
-
0024600990
-
Univariate analysis of prognostic factors in patients with advanced prostatic cancer: Results from two European organization for research on treatment of cancer trials
-
De Voogt H.J. S. Suciu R. Sylvester Univariate analysis of prognostic factors in patients with advanced prostatic cancer: Results from two European organization for research on treatment of cancer trials J Urol 141 1989 883 888
-
(1989)
J Urol
, vol.141
, pp. 883-888
-
-
De Voogt, H.J.1
Suciu, S.2
Sylvester, R.3
-
12
-
-
0018687833
-
Leukoerythroblastosis and cancer frequency, prognosis and physiologic significance
-
G. Delsol B. Guiu-Godfrin M. Guiu Leukoerythroblastosis and cancer frequency, prognosis and physiologic significance Cancer 44 1979 1009 1013
-
(1979)
Cancer
, vol.44
, pp. 1009-1013
-
-
Delsol, G.1
Guiu-Godfrin, B.2
Guiu, M.3
-
13
-
-
0031835943
-
European organization for research and treatment of cancer (EORTC) prostate cancer trials, 1976–1996
-
L. Denis European organization for research and treatment of cancer (EORTC) prostate cancer trials, 1976–1996 Urology 51 suppl 5A 1998 50 57
-
(1998)
Urology
, vol.51
, Issue.suppl 5A
, pp. 50-57
-
-
Denis, L.1
-
14
-
-
0020957960
-
A comparative clinical trial of Adriamycin and 5-Florouracil in advanced prostatic cancer: Prognostic factors and response
-
W.D. Dewys C.B. Begg H. Brodovsky A comparative clinical trial of Adriamycin and 5-Florouracil in advanced prostatic cancer: Prognostic factors and response Prostate 4 1983 1 11
-
(1983)
Prostate
, vol.4
, pp. 1-11
-
-
Dewys, W.D.1
Begg, C.B.2
Brodovsky, H.3
-
15
-
-
0022356273
-
Prognostic factors in patients with advanced prostate cancer
-
L.J. Emrich R.L. Priore G.P. Murphy Prognostic factors in patients with advanced prostate cancer Cancer Res 45 1985 5173 5179
-
(1985)
Cancer Res
, vol.45
, pp. 5173-5179
-
-
Emrich, L.J.1
Priore, R.L.2
Murphy, G.P.3
-
16
-
-
0026548628
-
Prostate-specific antigen and other prognostic factors in patients with hormone-resistant prostate cancer undergoing experimental treatment
-
S.D. Fossa E. Paus M. Lindegaard Prostate-specific antigen and other prognostic factors in patients with hormone-resistant prostate cancer undergoing experimental treatment Br J Urol 69 1992 175 179
-
(1992)
Br J Urol
, vol.69
, pp. 175-179
-
-
Fossa, S.D.1
Paus, E.2
Lindegaard, M.3
-
17
-
-
17444434615
-
Prognostic significance of detection of prostate-specific antigen transcripts in the peripheral blood of patients with metastatic androgen-independent prostatic carcinoma
-
R.A. Ghossein J. Rosai H.I. Scher Prognostic significance of detection of prostate-specific antigen transcripts in the peripheral blood of patients with metastatic androgen-independent prostatic carcinoma Urology 50 1997 100 105
-
(1997)
Urology
, vol.50
, pp. 100-105
-
-
Ghossein, R.A.1
Rosai, J.2
Scher, H.I.3
-
18
-
-
0015950349
-
Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging
-
D.F. Gleason G.T. Mellinger VACURG Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging J Urol 111 1974 58 64
-
(1974)
J Urol
, vol.111
, pp. 58-64
-
-
Gleason, D.F.1
Mellinger, G.T.2
VACURG3
-
19
-
-
0013890366
-
Classification of prostatic carcinomas
-
D.F. Gleason Classification of prostatic carcinomas Cancer Chemother Rep 50 1966 125 128
-
(1966)
Cancer Chemother Rep
, vol.50
, pp. 125-128
-
-
Gleason, D.F.1
-
20
-
-
0030297953
-
Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: A pilot study
-
C.S. Higano W. Ellis K. Russell Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: A pilot study Urology 48 1996 800 804
-
(1996)
Urology
, vol.48
, pp. 800-804
-
-
Higano, C.S.1
Ellis, W.2
Russell, K.3
-
21
-
-
0016721437
-
Carcinoma of the prostate: Correlation between radiologic quantification of metastases and patient survival
-
J.A. Hovsepian D.P. Byar VACURG Carcinoma of the prostate: Correlation between radiologic quantification of metastases and patient survival Urology 6 1975 11 16
-
(1975)
Urology
, vol.6
, pp. 11-16
-
-
Hovsepian, J.A.1
Byar, D.P.2
VACURG3
-
22
-
-
0028808702
-
Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer
-
G.R. Hudes F.E. Nathan C. Khater Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer Semin Oncol 22 1995 41 45
-
(1995)
Semin Oncol
, vol.22
, pp. 41-45
-
-
Hudes, G.R.1
Nathan, F.E.2
Khater, C.3
-
23
-
-
0027944451
-
Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: A southwest oncology group report
-
M. Hussain M. Wolf E. Marshall Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: A southwest oncology group report J Clin Oncol 12 1994 1868 1875
-
(1994)
J Clin Oncol
, vol.12
, pp. 1868-1875
-
-
Hussain, M.1
Wolf, M.2
Marshall, E.3
-
24
-
-
0031745738
-
A new parameter for measuring metastatic bone involvement by prostate cancer: The bone scan index
-
M. Imbriaco S.M. Larson H.W. Yeung A new parameter for measuring metastatic bone involvement by prostate cancer: The bone scan index Clin Cancer Res 4 1998 1765 1772
-
(1998)
Clin Cancer Res
, vol.4
, pp. 1765-1772
-
-
Imbriaco, M.1
Larson, S.M.2
Yeung, H.W.3
-
25
-
-
0017665658
-
Alkaline phosphatase in serum of patients with prostatic carcinoma
-
T. Ishibe Alkaline phosphatase in serum of patients with prostatic carcinoma Urology 10 1977 227 232
-
(1977)
Urology
, vol.10
, pp. 227-232
-
-
Ishibe, T.1
-
26
-
-
0027511899
-
Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer
-
W.K. Kelly H.I. Scher M. Mazumdar Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer J Clin Oncol 11 1993 607 615
-
(1993)
J Clin Oncol
, vol.11
, pp. 607-615
-
-
Kelly, W.K.1
Scher, H.I.2
Mazumdar, M.3
-
27
-
-
0028899680
-
Staging of prostate cancer: Accuracy of MRI imaging
-
C. Langlotz M. Schnall H. Pollack Staging of prostate cancer: Accuracy of MRI imaging Radiology 194 1995 645 646
-
(1995)
Radiology
, vol.194
, pp. 645-646
-
-
Langlotz, C.1
Schnall, M.2
Pollack, H.3
-
28
-
-
0031947670
-
Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer
-
C. Mahler J. Vehelst L. Denis Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer Clin Pharmacokinet 34 1998 405 417
-
(1998)
Clin Pharmacokinet
, vol.34
, pp. 405-417
-
-
Mahler, C.1
Vehelst, J.2
Denis, L.3
-
29
-
-
0024218086
-
Androgen priming and chemotherapy in advanced prostate cancer: Evaluation of determinants of clinical outcome
-
A. Manni M. Bartholomew R. Caplan Androgen priming and chemotherapy in advanced prostate cancer: Evaluation of determinants of clinical outcome J Clin Oncol 6 1988 1456 1466
-
(1988)
J Clin Oncol
, vol.6
, pp. 1456-1466
-
-
Manni, A.1
Bartholomew, M.2
Caplan, R.3
-
30
-
-
0026687613
-
Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer
-
H. Matzkin P. Eber B. Todd Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer Cancer 70 1992 2302 2309
-
(1992)
Cancer
, vol.70
, pp. 2302-2309
-
-
Matzkin, H.1
Eber, P.2
Todd, B.3
-
31
-
-
0026525245
-
The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer
-
J.I. Miller F.R. Ahmann G.W. Drach The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer J Urol 147 1992 956 961
-
(1992)
J Urol
, vol.147
, pp. 956-961
-
-
Miller, J.I.1
Ahmann, F.R.2
Drach, G.W.3
-
32
-
-
0030904147
-
Assessment of hormone refractory prostate cancer
-
D. Newling S.D. Fossa L. Andersson Assessment of hormone refractory prostate cancer Urology 49 4A suppl 1997 46 53
-
(1997)
Urology
, vol.49
, Issue.4A suppl
, pp. 46-53
-
-
Newling, D.1
Fossa, S.D.2
Andersson, L.3
-
33
-
-
0030659642
-
PSA evolution: A prognostic factor during treatment of advanced prostatic carcinoma with total androgen blockade
-
W. Oosterlinck J. Mattelaer J. Casselman PSA evolution: A prognostic factor during treatment of advanced prostatic carcinoma with total androgen blockade Acta Urol Belg 65 1997 63 71
-
(1997)
Acta Urol Belg
, vol.65
, pp. 63-71
-
-
Oosterlinck, W.1
Mattelaer, J.2
Casselman, J.3
-
34
-
-
0023881932
-
Prostate-specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy
-
J.E. Osterling D.W. Chan J.I. Epstein Prostate-specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy J Urol 139 1988 766 772
-
(1988)
J Urol
, vol.139
, pp. 766-772
-
-
Osterling, J.E.1
Chan, D.W.2
Epstein, J.I.3
-
35
-
-
0030913315
-
Combination of prostate-specific antigen, clinical stage, and gleason score to predict pathological stage of localized prostate cancer: A multi-institutional update
-
A.W. Partin M.W. Kattan E.W. Subong Combination of prostate-specific antigen, clinical stage, and gleason score to predict pathological stage of localized prostate cancer: A multi-institutional update JAMA 277 1997 1445 1451
-
(1997)
JAMA
, vol.277
, pp. 1445-1451
-
-
Partin, A.W.1
Kattan, M.W.2
Subong, E.W.3
-
36
-
-
0026441567
-
Prognostic factors for survival of patients with bidimensionally measurable metastatic hormone-refractory prostate cancer treated with single-agent chemotherapy
-
D.P. Petrylak H.I. Scher Z. Li Prognostic factors for survival of patients with bidimensionally measurable metastatic hormone-refractory prostate cancer treated with single-agent chemotherapy Cancer 70 1992 2870 2878
-
(1992)
Cancer
, vol.70
, pp. 2870-2878
-
-
Petrylak, D.P.1
Scher, H.I.2
Li, Z.3
-
37
-
-
0028104733
-
Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate
-
K.J. Pienta B. Redman M. Hussain Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate J Clin Oncol 12 1994 2005 2012
-
(1994)
J Clin Oncol
, vol.12
, pp. 2005-2012
-
-
Pienta, K.J.1
Redman, B.2
Hussain, M.3
-
38
-
-
0030782928
-
A phase II trial of oral estramustine and oral etoposide in hormone-refractory prostate cancer
-
K.J. Pienta B.G. Redman R. Bandekar A phase II trial of oral estramustine and oral etoposide in hormone-refractory prostate cancer Urology 50 1997 401 407
-
(1997)
Urology
, vol.50
, pp. 401-407
-
-
Pienta, K.J.1
Redman, B.G.2
Bandekar, R.3
-
39
-
-
0019523854
-
Nuclear bone imaging in metastatic cancer of the prostate
-
J.J. Pollen K. Gerber W.L. Ashburn Nuclear bone imaging in metastatic cancer of the prostate Cancer 47 1981 2585 2594
-
(1981)
Cancer
, vol.47
, pp. 2585-2594
-
-
Pollen, J.J.1
Gerber, K.2
Ashburn, W.L.3
-
40
-
-
0028298282
-
Symptomatology of metastatic prostate cancer: Prognostic significance
-
A. Rana G.D. Chisholm H.M. Rashwan Symptomatology of metastatic prostate cancer: Prognostic significance Br J Urol 73 1994 683 686
-
(1994)
Br J Urol
, vol.73
, pp. 683-686
-
-
Rana, A.1
Chisholm, G.D.2
Rashwan, H.M.3
-
41
-
-
84873795073
-
Metastases in bone marrow and myelophthisic anemia from carcinoma of the prostate
-
R.W. Rundles U. Jonsson Metastases in bone marrow and myelophthisic anemia from carcinoma of the prostate Am J Med Sci 218 1949 241 250
-
(1949)
Am J Med Sci
, vol.218
, pp. 241-250
-
-
Rundles, R.W.1
Jonsson, U.2
-
42
-
-
0025186406
-
Trimetrexate in prostatic cancer: Preliminary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease
-
H.I. Scher T. Curley N. Geller Trimetrexate in prostatic cancer: Preliminary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease J Clin Oncol 8 1990 1830 1838
-
(1990)
J Clin Oncol
, vol.8
, pp. 1830-1838
-
-
Scher, H.I.1
Curley, T.2
Geller, N.3
-
43
-
-
0028106791
-
Post-therapy change in prostate-specific antigen levels as a clinical trial endpoint in hormone-refractory prostatic cancer: A trial with 10-ethyl-deaza-aminopterin
-
P.K. Schultz W.K. Kelly C. Begg Post-therapy change in prostate-specific antigen levels as a clinical trial endpoint in hormone-refractory prostatic cancer: A trial with 10-ethyl-deaza-aminopterin Urology 44 1994 237 242
-
(1994)
Urology
, vol.44
, pp. 237-242
-
-
Schultz, P.K.1
Kelly, W.K.2
Begg, C.3
-
44
-
-
0031012183
-
Staging prostate cancer with MR imaging: A combined radiologist-computer system
-
S.E. Seltzer D.J. Getty C.M.C. Tempany Staging prostate cancer with MR imaging: A combined radiologist-computer system Radiology 202 1997 219 226
-
(1997)
Radiology
, vol.202
, pp. 219-226
-
-
Seltzer, S.E.1
Getty, D.J.2
Tempany, C.M.C.3
-
45
-
-
0027277127
-
Leukoerythroblastic anemia in metastatic prostate cancer
-
G.J. Shamdas F.R. Ahmann M.B. Matzner Leukoerythroblastic anemia in metastatic prostate cancer Cancer 71 1993 3594 3600
-
(1993)
Cancer
, vol.71
, pp. 3594-3600
-
-
Shamdas, G.J.1
Ahmann, F.R.2
Matzner, M.B.3
-
46
-
-
37049183697
-
Human breast cancer: Correlation of relapse and survival with amplification of HER-2/neu oncogene
-
D.J. Slamon G.M. Clark S.G. Wong Human breast cancer: Correlation of relapse and survival with amplification of HER-2/neu oncogene Science 235 1987 177 182
-
(1987)
Science
, vol.235
, pp. 177-182
-
-
Slamon, D.J.1
Clark, G.M.2
Wong, S.G.3
-
47
-
-
0031832733
-
Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer
-
D.C. Smith R.L. Dunn M.S. Strawderman Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer J Clin Oncol 16 1998 1835 1843
-
(1998)
J Clin Oncol
, vol.16
, pp. 1835-1843
-
-
Smith, D.C.1
Dunn, R.L.2
Strawderman, M.S.3
-
48
-
-
0023834161
-
Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan
-
M.S. Soloway S.W. Hardeman D. Hickey Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan Cancer 61 1988 195 202
-
(1988)
Cancer
, vol.61
, pp. 195-202
-
-
Soloway, M.S.1
Hardeman, S.W.2
Hickey, D.3
-
49
-
-
0028862179
-
Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy
-
R. Sridhara M.A. Eisenberger V.J. Sinibaldi Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy J Clin Oncol 13 1995 2944 2953
-
(1995)
J Clin Oncol
, vol.13
, pp. 2944-2953
-
-
Sridhara, R.1
Eisenberger, M.A.2
Sinibaldi, V.J.3
-
50
-
-
0030000896
-
Acid phosphatase: Defining the role in androgen-independent prostate cancer
-
G. Steineck W.K. Kelly M. Mazumdar Acid phosphatase: Defining the role in androgen-independent prostate cancer Urology 47 1996 719 726
-
(1996)
Urology
, vol.47
, pp. 719-726
-
-
Steineck, G.1
Kelly, W.K.2
Mazumdar, M.3
-
51
-
-
0032168442
-
Current status of intermittent androgen suppression in the treatment of prostate cancer
-
G. Thayer G. Hamilton Current status of intermittent androgen suppression in the treatment of prostate cancer Urology 52 1998 353 359
-
(1998)
Urology
, vol.52
, pp. 353-359
-
-
Thayer, G.1
Hamilton, G.2
-
52
-
-
0027311893
-
Prostate-specific antigen: An important marker for prostate cancer treated by external beam radiation therapy
-
Zagars G.K. von Eschenbach A.C. Prostate-specific antigen: An important marker for prostate cancer treated by external beam radiation therapy Cancer 72 1993 538 548
-
(1993)
Cancer
, vol.72
, pp. 538-548
-
-
Zagars, G.K.1
von Eschenbach, A.C.2
-
53
-
-
0029995206
-
Time to second prostate-specific antigen failure is a surrogate endpoint for prostate cancer death in a prospective trial of therapy for localized disease
-
A.L. Zietman K.C. Dallow P.A. McManus Time to second prostate-specific antigen failure is a surrogate endpoint for prostate cancer death in a prospective trial of therapy for localized disease Urology 47 1996 236 239
-
(1996)
Urology
, vol.47
, pp. 236-239
-
-
Zietman, A.L.1
Dallow, K.C.2
McManus, P.A.3
|